CORT vs XLI
Corcept Therapeutics Incorporated (CORT) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
XLI (XLI) common stock.
Latest reported CORT revenue for 2026-06-30 was $421.1M. Net income was $11.2M. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
XLI does not have a complete income-statement cache yet.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. XLI currently screens at market cap $0.
Not investment advice. Open the CORT and XLI stock pages for the full models.
Not investment advice.